Argenx and Chugai have entered into a research license and option agreement under which argenx may access Chugai’s SMART-Ig® and ACT-Ig®.
Lead Product(s): Engineered Antibodies
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 06, 2020